Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA.We are pioneering new territory, with an expedition led by a team of skilled scientists and drug development leaders who are inventive yet pragmatic. We are on a bold and exciting mission, a mission not without peril, but we have an energized, collaborative, creative and fearless team – a team that has consistently breached barriers and blazed new trails in search of solutions. We are now poised to realize the promise of bringing RNA into play for small-molecule drug discovery.Pushing the frontier of this emerging field of science is gratifying, but our mission goes beyond the thrill of scientific discovery.  We believe that by targeting RNA biology in new ways, we have the potential to impact millions of patients.  Our platform will allow us to reach hundreds of biological targets not currently accessible to medicine, including known targets previously considered “undruggable.” Our destination is powerful new therapies for patients everywhere, by opening up a new path for discovering RNA-targeted medicines.

WuXi AppTec

venBio Partners

Canaan Partners

Advent Life Sciences

Alexandria Venture Investments

Celgene

Nextech Invest

Omega Funds

OUP (Osage University Partners)

Henri Termeer

Arrakis Therapeutics

ReviR Therapeutics is a research and development company focused on the healthcare and biotechnology sectors. The company's main offerings include the development of novel medicines to treat human diseases, leveraging advanced technologies such as artificial intelligence and RNA biology.

ReviR Therapeutics

Regulus is a company focused on the development of RNA-targeted therapeutics for the treatment of various diseases.

Regulus

Sarepta Therapeutics is a biopharmaceutical company focused on the development of RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.

Sarepta Therapeutics

Alnylam is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics for the treatment of genetic and rare diseases.

Alnylam

Ribometrix is a drug discovery therapeutics company collaborating with Vertex Pharmaceuticals to discover small molecule drugs targeting functional 3D RNA structures to treat human diseases.

Ribometrix

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company has developed a proprietary platform to identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Arrakis is building a proprietary pipeline of RNA-targeted small molecules (rSMs) focused on cancer and genetically validated targets in other disease areas.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 5, 2024 10:38 AM	6a4c4ea7
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 10:38 AM	a4a7b041
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	1280343a
crunchbase profile	general
li profile	general	Mar 5, 2024 10:38 AM	399667c5
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 5, 2024 10:38 AM	d0b846cd
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ARRAKISTX

Arrakis Therapeutics